Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMEGN5I)

Drug Name
HMPL-689 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Cross-matching ID
PubChem CID
118981804
TTD Drug ID
DMEGN5I

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
PI3-kinase delta (PIK3CD) DTT PIK3CD 5.711 5.814 6.011 6.508
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase delta (PIK3CD) DTT PIK3CD 4.31E-16 -0.37 -0.91
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03786926) Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Hutchison MediPharma.